Literature DB >> 30107154

Human cryptosporidiosis in immunodeficient patients in France (2015-2017).

Damien Costa1, Romy Razakandrainibe2, Marc Sautour3, Stéphane Valot3, Louise Basmaciyan3, Gilles Gargala2, Denis Lemeteil4, Loïc Favennec2, Frédéric Dalle3.   

Abstract

Cryptosporidiosis is a common disease in children and immunodeficient individuals. In 2006, a national network was set up on the surveillance of human cryptosporidiosis in France. Since January 2015, the 41 tertiary care hospitals and the 3 private laboratories of the French National Network on the surveillance of human cryptosporidiosis have been able to declare confirmed cases of cryptosporidiosis online. Between 2015 and 2017, 210 cases of cryptosporidiosis were declared in immunodeficient patients in France; Cryptosporidium parvum and Cryptosporidium hominis represented 66% and 22% of cases, respectively. A peak was observed in autumn. Cryptosporidiosis occurred mainly in a context of solid organ transplantation (SOT) (49%) and of HIV infection (30%). In SOT recipients, cryptosporidiosis appeared more frequently in the first 6 months post transplantation. Regarding cases declared in SOT recipients, mycophenolate mofetil was used in 68%. A mortality rate of 6% was observed. Present results underline the importance of screening for cryptosporidiosis in immunocompromised patients suffering from diarrhea, especially in the course of major cell mediated immunodeficiency or even systematic screening before SOT. Exclusive Cryptosporidium free water feeding could be suggested during major cell mediated immunodeficiency.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cryptosporidiosis; Epidemiology; France; Immunocompromised; Protozoan

Mesh:

Substances:

Year:  2018        PMID: 30107154     DOI: 10.1016/j.exppara.2018.08.001

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  8 in total

1.  Effect of Caging on Cryptosporidium parvum Proliferation in Mice.

Authors:  Hannah N Creasey; Wen Zhang; Giovanni Widmer
Journal:  Microorganisms       Date:  2022-06-17

2.  High Diversity of Cryptosporidium Species and Subtypes Identified in Cryptosporidiosis Acquired in Sweden and Abroad.

Authors:  Marianne Lebbad; Jadwiga Winiecka-Krusnell; Christen Rune Stensvold; Jessica Beser
Journal:  Pathogens       Date:  2021-04-26

Review 3.  Use-case scenarios for an anti-Cryptosporidium therapeutic.

Authors:  Paul G Ashigbie; Susan Shepherd; Kevin L Steiner; Beatrice Amadi; Natasha Aziz; Ujjini H Manjunatha; Jonathan M Spector; Thierry T Diagana; Paul Kelly
Journal:  PLoS Negl Trop Dis       Date:  2021-03-11

4.  Resolution of Cryptosporidiosis in Transplant Recipients: Review of the Literature and Presentation of a Renal Transplant Patient Treated With Nitazoxanide, Azithromycin, and Rifaximin.

Authors:  Ewa Tomczak; April N McDougal; A Clinton White
Journal:  Open Forum Infect Dis       Date:  2021-12-04       Impact factor: 3.835

5.  Occurrence of cryptosporidium parvum IIaA17G1R1 in hospitalized hemato-oncological patients in Slovakia.

Authors:  Elena Hatalova; Tomas Guman; Veronika Bednarova; Vladimira Turcok Simova; Mariia Logoida; Monika Halanova
Journal:  Parasitol Res       Date:  2021-11-04       Impact factor: 2.289

6.  Molecular Detection of Cryptosporidium cuniculus in Rabbits (Oryctolagus cuniculus) from Tenerife, Canary Islands, Spain.

Authors:  Edgar Baz-González; Natalia Martín-Carrillo; Katherine García-Livia; Pilar Foronda
Journal:  Vet Sci       Date:  2022-02-18

7.  Comparative Performance of Eight PCR Methods to Detect Cryptosporidium Species.

Authors:  Damien Costa; Louise Soulieux; Romy Razakandrainibe; Louise Basmaciyan; Gilles Gargala; Stéphane Valot; Frédéric Dalle; Loic Favennec
Journal:  Pathogens       Date:  2021-05-23

Review 8.  Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review.

Authors:  M Martinot; A Abou-Bacar; M Lamothe; M Alt Tebacher; M Mohseni Zadeh; F Dalle; L Favennec; D Costa; J Brunet; F Sellal
Journal:  BMC Infect Dis       Date:  2020-03-30       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.